CD274 and head and neck squamous cell carcinoma: However, one promising clinical PD1/-L1 imaging study is upcoming with the PINCH trial (NCT03829007; PINCH – PD-L1 ImagiNg to predict Durvalumab Treatment Response in HNSCC), measuring the uptake of 89Zr-durvalumab in 58 participants with relapsed or metastatic HNSCC [104].